Filtern
Volltext vorhanden
- ja (7)
Gehört zur Bibliographie
- ja (7)
Erscheinungsjahr
- 2008 (7) (entfernen)
Dokumenttyp
- Dissertation (7)
Schlagworte
- Apoptosis (2)
- Androgenetic (1)
- Androgenetisch (1)
- BAD (1)
- BCL-2 Familie (1)
- BCL-2 family (1)
- Beta-catenin (1)
- Biochemische Kontrolle (1)
- C-RAF (1)
- Caspase-1 (1)
Institut
- Institut für Medizinische Strahlenkunde und Zellforschung (7) (entfernen)
Uniparental zygotes with two genomes from the same sex can be established from fertilised oocytes after pronuclear exchange. They contain two maternal (gynogenetic; GG) or paternal (androgenetic; AG) pronuclei and are not competent to develop into viable offspring but they can form blastocysts from which embryonic stem cells (ES cells) can be derived. The developmental potential of uniparental ES cells is not fully investigated. The restricted developmental potential of uniparental cells is cell-intrinsic and probably reflects the different roles maternal and paternal genomes play during development. Following blastocyst injection, both GG and AG ES cells show biased and parent-of-origin-specific chimaera formation. While the in vitro and in vivo neural differentiation potential of GG ES cells is well characterised the neural developmental potential of AG ES cells is less clear. In an earlier study the group of K. John McLaughlin reported that AG and GG ES cell-derived hematopoietic stem cells conveyed long-term, multi-lineage hematopoietic engraftment with no associated pathologies (Eckardt et al., 2007). The aim of this study was to investigate the potential of AG uniparental murine ES cells to differentiate in vitro and in vivo into neural progenitor / stem cells and further into neurons, astro- and oligodendroglia in comparison to GG and biparental (normal fertilised; N) ES cells. Uniparental and biparental ES cells were obtained from K. John McLaughlin’s group and a cell culture system was established to expand uniparental (AG, GG) and biparental N ES cells on murine embryonic fibroblasts (MEF). A multistep-protocol was used to differentiate ES cells towards pan-neural progenitor cells and neuronal and glial cell types (Brüstle et al., 1997). The ability of terminal neural differentiation in vitro was analysed by fluorescence microscopy using neuronal and glial lineage markers. In parallel, eGFP+ AG or N ES cells were injected into blastocysts prior to their transfer into foster mothers. At E12.5 and E14.5, embryos were isolated, forebrains were dissected and by means of fluorescence activated cell sorting (FACS) eGFP+ donor cells were isolated from chimeric brains. Both eGFP+ donor and corresponding eGFP- blastocyst-derived brain cells were expanded and analyses of differentiation potential and self-renewal capacity were performed. Also, cryosections of E12.5 chimeric brains were analysed for donor contribution to the neuronal lineage by immunofluorescence microscopy. Here it is described that following in vitro differentiation, AG pan-neural progenitor cells have similar abilities to differentiate into neuronal and glial lineages as GG and N pan-neural progenitor cells. In cryosections of E12.5 chimeric brains no differences in brain engraftment and formation of immature neuronal cells between uniparental AG and N donor cells were detected. AG and N ES cell-derived cells isolated from chimeric foetal brains by FACS exhibited similar neurosphere initiating cell frequencies and neural multi-lineage differentiation potential. Therefore, the data of this study suggest that the previously described differences in the in vivo engraftment pattern of uniparental inner cell mass (ICM) cells in foetal brains (Keverne et al., 1996) are not primarily due to limitations in the proliferation or differentiation properties of uniparental neural progenitor cells. The results presented here indicate that AG ES cell-derived neural progenitor / stem cells did not differ from N neural progenitor / stem cells in their self-renewal and their neural multi-lineage differentiation potential. Also AG ES cell-derived cells contributed to developing brains at early foetal developmental stages showing a widespread and balanced distribution in chimeric brains. AG brain cells form neurospheres with self-renewal and neural differentiation capacity similar to N ES cell-derived brain cells. Thus, the data of this study together indicate that the neural developmental potential in vivo and in vitro of AG and N ES cells does not differ.
In neoplastic diseases the tumor stroma and especially tumor-associated macrophages (TAMs) play an important role in tumor growth and progression. TAMs exhibit an intensive cross-talk with tumor cells resulting in the promotion of angiogenesis and the inhibition of local protective immune responses in certain tumor entities. Therefore, TAMs are a potential target for tumor therapy. Here it was shown that intravenously applied intracellular bacteria like Salmonella and Shigella primarily target TAMs. To exploit this feature a growth attenuated Shigella strain with the capacity to induce apoptosis in macrophages was designed. Shigella are invasive bacteria that penetrate the colonic tissue and initiate an acute inflammation. In macrophages, Shigella rapidly induces caspase-1 processing and apoptosis via the virulence factor IpaB. By genomic deletion of the aroA-locus a metabolically attenuated strain defective in intracellular growth but with retained capacity of infection, cell-to-cell spread, caspase-1 processing and apoptosis induction in macrophages was designed. It was shown that this strain primarily targets TAMs in 4T1 cell induced and transgenic MMTV-HER2/new breast cancer models. Shigella were almost exclusively found intracellularly, whereas growth attenuated Salmonella were also found extracellularly at late time points. The metabollically attenuated Shigella strain with retained virulence, but not avirulent Shigella strains, was able to activate caspase-1 and induce apoptosis in TAMs at all time points (4 h, 6 h and 7 d p.i.) in both breast cancer models. This unrestricted apoptosis induction translated into a substantial, long-lasting and highly significant reduction of TAMs number (up to 70 %) in both models. In contrast, Salmonella could only induce apoptosis in TAMs at early time points (6 h p.i.) and failed to reduce TAMs in both models. In the 4T1 model, the effect on tumor size was monitored and treatment of the mice with the attenuated Shigella strain resulted in a complete block of tumor growth. Finally, Shigella primarily infected the macrophage fraction, activated caspase-1 and induced apoptosis in cells derived from a human ovarian carcinoma ex vivo. Taken together, this data suggests that growth attenuated intracellular bacteria capable of inducing apoptosis in TAMs are a promising therapeutic option for certain cancer diseases where TAMs have a proven role for tumor growth or progression.
Gegenstand dieser Arbeit ist das Drosophila melanogaster Protein DPAK3, ein Vertreter der hochkonservierten Familie der p21-aktivierten Kinasen (PAK). DPAK3 und seine Homologen aus anderen Insektenarten und C. elegans können aufgrund eines Vergleichs der Proteinsequenz und struktureller Merkmale in eine eigenen Untergruppe 1* innerhalb der Gruppe 1 der PAK-Proteine eingeordnet werden. Das Genom von Drosophila kodiert noch für zwei weitere PAK-Proteine, das zur Gruppe 1 gehörende DPAK1 und das Gruppe 2 PAK-Protein Mbt. Wie die klassischen Gruppe 1 PAK-Proteine bildet DPAK3 im inaktiven Zustand Dimere. DPAK3 interagiert mit den GTP-gebundenen Formen der RhoGTPasen Rac1, Rac2 und Cdc42. Durch die Bindung dieser Proteine geht DPAK3 aus dem dimeren in den monomeren Zustand über und seine Kinaseaktivität wird durch diese Bindung gesteigert. DPAK3 ist für die Ausbildung der korrekten Morphologie kultivierter Drosophila Zellen erforderlich und beeinflußt die Regulation des Aktinzytoskeletts. Weiterhin konnte CK2beta, die regulatorische Untereinheit der Casein Kinase 2, als neuer Regulator von p21-aktivierten Kinasen identifiziert werden. Das Genom von Drosophila besitzt drei Transkriptionseinheiten, die für CK2beta', CK2betatestes und fünf verschiedene Isoformen von CK2beta kodieren. Eine vergleichende Analyse zeigt, daß alle CK2beta-Proteine mit DPAK1, DPAK3 und in geringerem Maß auch mit Mbt interagieren und in der Lage sind, die Aktivität der PAK-Proteine in vitro zu hemmen. Die Bindung von CK2beta an DPAK3 wird, wie bei allen anderen Serin- / Threoninkinasen, die bisher als Interaktionspartner von CK2beta identifiziert wurden, über die Kinasedomäne von DPAK3 vermittelt. Die Bildung des aus zwei katalytischen CK2a und zwei CK2beta Untereinheiten bestehenden CK2-Holoenzyms hängt von der Fähigkeit von CK2beta ab, Dimere zu bilden. Es konnte gezeigt werden, daß die Bildung eines b-b Dimers für die Interaktion mit und Regulation von DPAK3 nicht erforderlich ist. In vivo wurden die bisher bekannten Dpak3 Allele untersucht, wobei kein gesichertes Nullallel identifiziert werden konnte. Durch enzymatisch katalysierte Rekombination wurde eine neue Deletion hergestellt, die das komplette Leseraster von Dpak3 entfernt. Mit Hilfe von genetischen Mosaiken wurde die Rolle von DPAK3 in der Augenentwicklung untersucht. Durch den Verlust der Genfunktion von Dpak3 wird die Ausbildung der korrekten Struktur der Komplexaugen nur leicht beeinträchtigt. Bei der Analyse einer Dpak1 Mutante wurde dasselbe Ergebnis erzielt. Gleichzeitiger Verlust der Genfunktion von Dpak1 und Dpak3 hingegen führt zu massiven strukturellen Defekten. DPAK1 und DPAK3 erfüllen somit zumindest teilweise redundante Funktionen in der Augenentwicklung. Es wird Gegenstand zukünftiger Studien sein müssen, die gemeinsamen und getrennten Funktionen dieser PAK-Proteine in Drosophila aufzuklären.
Steps involved in the progression of non-small cell lung cancer (NSCLC) to metastasis are poorly understood. Expression of oncogenic C-RAF in lung epithelial cells has yielded a model for non-small cell lung cancer (NSCLC). The induced adenomas are characterised by high genomic stability, a lack of tumor progression and pronounced cell-cell contacts raising the question whether disruption of E-cadherin complexes would promote progression to metastasis. Two genetic approaches were used to evaluate the role of adherens junctions in a C-RAF driven mouse model for NSCLC: conditional ablation of the Cdh1 gene and expression of dominant negative (dn) E-cadherin. Disruption of E-cadherin function caused massive formation of intratumoral vessels that was reversible in the early phase of induction. Vascularized tumors grew more rapidly, developed invasive fronts and gave rise to micrometastasis. ß-catenin was identified as a critical effector of E-cadherin disruption leading to up-regulation of angiogenic inducers (VEGF-A and VEGF-C) in mouse and human lung tumor cell lines. In vivo, lung tumor cells with disrupted E-cadherin expressed ß-catenin target genes of endodermal and other lineages suggesting that reprogramming may be involved in metastatic progression.
Ziel der vorliegenden Arbeit war die Analyse der Versorgungsstrukturen in der postoperativen Strahlentherapie des Prostatakarzinoms in Nordbayern, um für den Behandlungszeitraum von 1998 bis 2000 Patientenselektion, Behandlungskonzepte und Ergebnisse auf der Ebene eines regionalen Qualitätszirkels zu charakterisieren. Hierfür wurden die Daten von 134 in kurativer Absicht postoperativ perkutan bestrahlter Patienten aus den strahlentherapeutischen Abteilungen von vier fränkischen Kliniken ausgewertet. Als Endpunkte dieser Patterns of Care Studie wurden das Gesamtüberleben und die biochemische Kontrolle (ASTRO-Kriterien mit Rückdatierung) analysiert. Bei der Datenauswertung wurde evident, dass das untersuchte Patientenkollektiv eine ausgeprägte Heterogenität bezüglich der klinischen Eigenschaften aufweist. Diese Studie offenbart somit, dass die Zuweiser im Untersuchungszeitraum die Patienten anhand unterschiedlicher Kriterien sowohl zur Operation als auch zur postoperativen Strahlentherapie selektierten. So differierten Resektionsgrad sowie initialer PSA-Wert zwischen den beteiligten Zentren signifikant. Wesentlich homogener erschien das Patientengut im Hinblick auf Alter, Gleason-Score sowie den pT- und pN- Stadien. Die vorliegende Analyse dokumentiert darüber hinaus die unterschiedlichen strahlentherapeutischen Konzepte im Untersuchungszeitraum von 1998-2000. Ein signifikanter Unterschied zwischen den Zentren im Behandlungsregime ergab sich in der Zielvolumendefinition, wohingegen die applizierten Gesamtdosen vergleichbar waren. Die mittlere Nachbeobachtungszeit lag insgesamt bei 4,8 Jahren. Die aktuarische biochemische Kontrolle nach 5 Jahren betrug 82,1%. Sie variierte zwischen den Zentren nicht signifikant von 63,8% bis 100%. Bei multivariater Analyse zeigte sich, dass die biochemische Kontrolle mit dem Alter und dem initialen PSA-Wert assoziiert war. Das 5-Jahres-Gesamtüberleben betrug 93,9% und variierte ebenfalls nicht signifikant zwischen 88,9% (Zentrum 3) und 94,7% (Zentrum 4). Die Erfassung von Akut- und Spättoxizitäten waren nicht Gegenstand der vorliegenden Untersuchung. Die von Zentrum zu Zentrum unterschiedliche Form der Dokumentation von Akutreaktionen während der Strahlentherapie sowie die nur in geringem Umfange vorliegenden Angaben zu Spätfolgen der Strahlentherapie ließen eine einheitliche Graduierung sowie eine Vergleichbarkeit von Toxizitätsdaten zwischen den Zentren als nicht realistisch erscheinen. Abschließend lässt sich festhalten, dass die Daten eine sehr heterogene Indikationsstellung und insbesondere im Hinblick auf die Zielvolumendefinition eine heterogene Durchführung der postoperativen Strahlentherapie dokumentieren. Dies mag darin mitbegründet sein, dass zum Untersuchungszeitraum keine einheitlichen Leitlinien für das Prostatakarzinom verfügbar waren. Ziele der evidenzbasierten Medizin könnten somit zukünftig sein, Kriterien für eine verbesserte Patientenselektion zu finden und therapeutische Richtlinien in die Praxis zu transferieren. Vielfältige Diskussionen, beispielsweise der Zielvolumendefinition sowie der Therapiealternativen sind gegenwärtig am Beginn. Weitere klinische Studien werden initiiert und deren Ergebnisse abgewartet werden müssen, bis validierte Empfehlungen als Standards etabliert werden können.
The proteins of the RAF family (A-RAF, B-RAF, and C-RAF) are serine/threonine-kinases that play important roles in development, mature cell regulation and cancer. Although it is widely held that their localization on membranes is an important aspect of their function, there are few data addressing this aspect of their mode of action. Here, we report that each member of the RAF family exhibits a specific distribution at the level of cellular membranes, and that C-RAF is the only isoform that directly targets mitochondria. We find that the RAF kinases exhibit intrinsic differences in terms of mitochondrial affinity, and that C-RAF is the only isoform that binds this organelle efficiently. This affinity is conferred by the C-RAF amino-terminal domain, and does not depend on the presence of RAS GTPases on the surface of mitochondria. Furthermore, we analyze the consequences of C-RAF activation on the cellular and molecular level. C-RAF activation on mitochondria dramatically changes their morphology and their subcellular distribution. On the molecular level, we examine the role of C-RAF in the regulation of the pro-apoptotic Bcl-2 family member BAD. This protein exhibits the original mode of regulation by phosphorylation. Although several reports addressed the regulation of BAD by C-RAF, the exact mode of action as well as the consequences of C-RAF activation on BAD are still not completely understood. We show that the inducible activation of C-RAF promotes the rapid phosphorylation of BAD on Serine-112 (Ser-75 in the human protein), through a cascade involving the kinases MEK and RSK. Our findings reveal a new aspect of the regulation of BAD protein and its control by the RAF pathway: we find that C-RAF activation promotes BAD poly-ubiquitylation in a phosphorylation-dependent fashion, and increases the turn-over of this protein through proteasomal degradation.
In neurons the Ras signaling pathway is activated by a large number of various stimuli, including trophic factors, neurotransmitters and modulatory peptides. Guanine nucleotide exchange factors (GEFs) mediate the activation of Ras GTPases, by catalyzing the exchange of GDP for GTP, and facilitate signaling networks crosstalk. In this work, very-KIND (VKIND), a new brain specific RasGEF was structurally and functionally characterized. VKIND belongs to the KIND protein family along with the non-receptor tyrosine phosphatases type 13 and Spir actin nucleation factors. The kinase non-catalytic C-lobe domain (KIND) is similar to the C-terminal protein kinase catalytic fold (C-lobe) of the p21-activated kinase (PAK). The open reading frame (ORF) of the VKIND gene of 5229 base pairs was cloned. The VKIND ORF translates into a protein of 1742 amino acids residues with a size of 191 kD. The VKIND protein structure is highly conserved among species and at present the protein is found only in Vertebratae and Echinodermatae. The arrangement of two KIND domains at its amino-terminal region, KIND1 and KIND2, is depicted in its name. The KIND module functions as a molecular interaction structure that is deprived of any enzymatic activity. While the precise occupation of the KIND1 domain remains elusive, the KIND2 domain binds to the microtubules-associated protein 2 (MAP2). The protein central portion features two clusters of high conservation of yet unknown function as well as a coiled-coil motif with a putative multiple protein-protein interaction activity. At the carboxy-terminal region VKIND features a guanine nucleotide exchange factor for Ras-like small GTPases (RasGEF) with a structural RasGEFN motif attached at its N-terminal site. The VKIND RasGEF motif is structurally related to the yeast catalytic domain CDC25. The closest relation of the VKIND RasGEF domain with an average sequence identity of 23% is assigned to the RasGEF domains of exchange factors specific for Rap GTPases with two unique insertions: the first one of 24 amino acids in the N-terminal end of the domain (between helixes αA and αB of the SOS1 RasGEF module) and the second one of 11 amino acids in the C-terminal part (between, helixes αJ and αK of the Sos1 RasGEF module). The RasGEFN domain plays a critical role in sustaining the structural and catalytical integrity of the guanidine exchange factor. VKIND is specifically and highly expressed in the murine nervous system during embryonic development and adulthood. During embryogenesis VKIND expression is present in the murine neural tube, telencephalon, retinal ganglion cells, and rhombencephalon. In the adult murine brain VKIND expression is most prominent in the cerebellum, however exclusively restricted to the granular and Purkinje cell layers. Subcellular distribution studies and time-lapse analysis revealed the gradual accumulation of VKIND into highly motile circular particles which featured estimated maximum velocity of 12 μm/min. By merging the nascent structures progressively grew to estimated 2 μm in size suggesting a role for VKIND in the vesicular transport process. Furthermore, the KIND1/KIND2 region of the VKIND protein was found to be phosphorylated by the p38 mitogen-activated protein kinase (MAPK), recently discovered to induce neurite outgrowth in response to hyperosmotic shock. In the light of VKIND negatively controlling neurite outgrowth, further elucidation of the complex Ras pathways may provide rewarding insights in the neuronal physiology.